<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1501244724
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOROXIN 400MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NORFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Algorithm SAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Noroxin&reg; belongs to a group of antibiotics called<br />quinolones. It is used to treat some bacterial<br />infections, such as:<br />- urinary tract infections (uncomplicated urinary tract<br />infections including cystitis and complicated urinary<br />tract infections)&nbsp;- sexually transmitted diseases (uncomplicated<br />urethral and cervical gonorrhea due to Neisseria<br />gonorrhea)<br />- Prostatitis (due to Escherichia coli)<br />In women, the most common infection involves the<br />bladder and is called cystitis. In men, the infection<br />may involve the prostate which is called prostatitis. In<br />both men and women, the bacteria may travel up and<br />infect to the kidneys.<br />The symptoms of a urinary tract infection may include<br />an urge to urinate frequently and in small amounts,<br />and painful burning when passing urine. Urinary tract<br />infections should be treated to avoid the kidneys<br />being infected.<br />Noroxin&reg; works by killing the bacteria causing the<br />infection. Your doctor may have prescribed Noroxin&reg;<br />for another reason.<br />Noroxin&reg; should not be used in patients with acute<br />exacerbation of chronic bronchitis, acute<br />uncomplicated cystitis, and sinus infections, if there<br />are other treatment options available.<br />Noroxin&reg; should not be used as the first choice of<br />antibacterial medicine to treat lower respiratory tract<br />infections caused by a certain type of bacteria called<br />Streptococcus pneumonia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Noroxin&reg; tablets are not for use in children under 18<br />years of age. Children have a higher chance of getting<br />bone and joint (musculoskeletal) problems while<br />taking Noroxin&reg;.<br />Do not take Noroxin&reg; if:<br />- You have an allergy to Noroxin&reg;, other quinolone<br />antibiotics or any of the ingredients listed at the end<br />of this leaflet (See section 7). Symptoms of an allergic<br />reaction to Noroxin&reg; may include itchiness, hives,<br />swelling of the face, lips, tongue, and/or throat<br />(which may cause difficulty in breathing or<br />swallowing), muscle pain or tenderness, or joint pain.<br />- You are pregnant or breast-feeding.<br />- You have had pain, inflammation or rupture of<br />tendons after taking quinolone.<br />If you are not sure whether you should start taking<br />Noroxin&reg;, talk to your doctor.<br />Take special care with Noroxin&reg;</p><p>Tell your healthcare provider about all your medical<br />conditions, including if you:<br />- have tendon problems<br />- have myasthenia gravis, a disease that causes<br />muscle weakness<br />- have central Nervous system problems (such as<br />epilepsy)<br />- have a nerve problem: Noroxin&reg; should not be<br />used in patients with a history of a peripheral<br />neuropathy<br />- have or have a family history of irregular<br />heartbeat, i.e. &ldquo;QTc prolongation&rdquo;<br />- have low potassium (hypokalemia)<br />- have a slow heartbeat called bradycardia<br />- have a history of seizures<br />- have kidney problems. You may need a lower<br />dose of Noroxin&reg;<br />- have rheumatoid arthritis (RA) or other history of<br />joint problems (family history of connective tissue<br />disorders, Behcet&rsquo;s disease)<br />- suffer from psychiatric disorder, hallucinations<br />and/or confusion<br />- have or anyone in your family has a deficiency<br />disorder called G-6-PD (glucose-6-phosphate<br />dehydrogenase deficiency), where you become<br />anemic after taking certain drugs<br />- have been diagnosed with an enlargement or<br />&ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm<br />or large vessel peripheral aneurysm)<br />- have experienced an episode of aortic dissection<br />(a tear in the aorta wall)<br />- Risk for heart valve regurgitation/ incompetence<br />(high blood pressure)<br />-<br />- Seek immediately an emergency room or medical<br />attention, if:<br />- You feel sudden shortness of breath, heart<br />palpitations, development of water retention of<br />your abdomen or lower extremities go<br />immediately to an emergency room and seek<br />medical attention.<br />- your eyesight becomes impaired of if your eyes<br />seem to be otherwise affected<br />- heartbeat, i.e. &ldquo;QTc prolongation&rdquo;<br />- have low potassium (hypokalemia)<br />- have a slow heartbeat called bradycardia<br />- have a history of seizures<br />- have kidney problems. You may need a lower<br />dose of Noroxin&reg;<br />- have rheumatoid arthritis (RA) or other history of<br />joint problems (family history of connective tissue</p><p>disorders, Behcet&rsquo;s disease)<br />- suffer from psychiatric disorder, hallucinations<br />and/or confusion<br />- have or anyone in your family has a deficiency<br />disorder called G-6-PD (glucose-6-phosphate<br />dehydrogenase deficiency), where you become<br />anemic after taking certain drugs<br />- have been diagnosed with an enlargement or<br />&ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm<br />or large vessel peripheral aneurysm)<br />- have experienced an episode of aortic dissection<br />(a tear in the aorta wall)<br />- Risk for heart valve regurgitation/ incompetence<br />(high blood pressure)<br />Seek immediately an emergency room or medical<br />attention, if:<br />- You feel sudden shortness of breath, heart<br />palpitations, development of water retention of<br />your abdomen or lower extremities go<br />immediately to an emergency room and seek<br />medical attention.<br />- your eyesight becomes impaired of if your eyes<br />seem to be otherwise affected<br />Taking Noroxin&reg; with other medicines<br />Tell your doctor or pharmacist if you are taking or<br />have recently taken any other medicines, including<br />prescription and nonprescription medicines, vitamins<br />and herbal and dietary supplements. Noroxin&reg; and<br />other medicines can affect each other causing side<br />effects. These include:<br />- Nitrofurantoin, another antibiotic used to<br />treat urinary tract infections<br />- Non-steroidal Anti-inflammatory drugs (NSAIDs),<br />many medicines for pain relief are NSAIDs. Taking<br />an NSAID while you take Noroxin&reg; or other<br />fluoroquinolones may increase your risk of<br />central nervous system effects and seizures.<br />- Glyburide, glibenclamide, a medicine used to<br />treat diabetes<br />- Blood thinners (warfarin, Coumadin)<br />- Medicines used to control your heart rate or<br />rhythm (antiarrhythmic) such as sotalol,<br />amiodarone, quinidine and procainamide<br />- antipsychotics<br />- tricyclic antidepressants, such as amitriptyline &amp;<br />nortriptyline<br />- erythromycin, another type of antibiotic<br />- probenecid, a medicine used to treat gout<br />- cyclosporin, a medicine commonly used in</p><p>patients with organ transplants<br />- products that contain caffeine<br />- certain medicines that are metabolized by a<br />specific enzyme in the liver such as: caffeine,<br />clozapine, ropinirole, tacrine, theophylline,<br />tizanidine<br />- theophylline, a medicine used to treat asthma<br />- cisapride, a medicine used to treat discomfort<br />due to the stomach acid flowing the wrong way<br />up the esophagus (also called the food pipe)<br />Certain medicines may be affected by Noroxin&reg;, or<br />may affect how well it works. Take Noroxin&reg; either 2<br />hours before or 2 hours after these products:<br />- antacids used for indigestion<br />- sucralfate, a medicine used to treat stomach<br />ulcers<br />- didanosine (ddI), a medicine used to treat HIV<br />infection.<br />- iron or zinc supplements, and multivitamins<br />containing them<br />Ask your healthcare provider if you are not sure if<br />your medicine is listed above.<br />Know the medicines you take. Keep a list of your<br />medicines and show it to your doctor or pharmacist<br />when you get a new medicine.<br />Pregnancy, breast-feeding and fertility<br />If you are pregnant, planning a family or breastfeeding,<br />tell your doctor before taking this medicine,<br />as it is not recommended for use under these<br />conditions.<br />Driving and using machines<br />Driving, operating machinery or doing any other<br />activities that require mental alertness or<br />coordination until you know how Noroxin&reg; affects<br />you. Noroxin&reg; can make you feel dizzy and<br />lightheaded.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Noroxin&reg; exactly as your doctor has told<br />you. You should check with your doctor or pharmacist<br />if you are not sure.<br />Taking this medicine<br />- Swallow the tablets whole with a glass of water.<br />Drink plenty of fluids while taking Noroxin&reg;<br />- Noroxin&reg; is usually taken every 12 hours for<br />patients with normal kidney function.<br />- Take Noroxin&reg; on an empty stomach, at least one<br />hour before food or two hours after food.<br />How much to take<br />- Take Noroxin&reg; only when prescribed by your<br />doctor.<br />- Your doctor will tell you how many tablets you<br />need to take each day.<br />- The usual dose of Noroxin&reg; is one tablet (400 mg<br />norfloxacin) twice a day for patients with normal<br />kidney function<br />- In case of patients with kidney problems:<br />- If you suffer from severe renal impairment, your<br />doctor may adjust your dosage. The<br />recommended dose is 1 tablet (400 mg<br />norfloxacin) once daily.<br />Preferably the tablets should be taken in the morning<br />and evening. If you only take a single daily dose,<br />always take this at the same time of day.<br />How long to take Noroxin&reg;?<br />Continue taking Noroxin&reg; until you finish the pack or<br />as recommended by your doctor.<br />- For treatment of urinary tract infections: The<br />length of treatment may vary from three to ten<br />days.<br />- To help stop frequent urinary tract infections<br />from coming back: You may need to take<br />Noroxin&reg; for up to 12 weeks.<br />If you take more Noroxin&reg; than you should<br />Tell a doctor or go to the nearest hospital casualty<br />department straight away. Do not drive to the<br />hospital, get somebody else to take you or call for an<br />ambulance. Take the medicine pack with you. This is<br />so the doctor knows what you have taken.<br />If you forget to take Noroxin&reg;<br />If you miss a dose, take your normal dose as soon as<br />you remember.</p><p>If it is almost time for your next dose, skip the missed<br />dose and continue with the regular dosing schedule.<br />Do not take two doses of Noroxin&reg; at the same time.<br />Do not take more than 2 doses of Noroxin&reg; in one day<br />While taking Noxorin&reg;, you should avoid<br />- Sunlamps and tanning beds, and try to limit your<br />time in the sun. Noroxin&reg; can make your skin<br />sensitive (photosensitivity). You could get severe<br />sunburn, blisters or swelling of your skin. If you<br />get any of these symptoms while taking Noroxin&reg;,<br />call your healthcare provider right away. You<br />should use sunscreen and wear a hat and clothes<br />that cover your skin if you have to be in sunlight.<br />If you have any further questions on the use of this<br />product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. Serious Adverse Events<br />Noroxin&reg; belongs to a class of antibiotics called<br />fluoroquinolones. Noroxin&reg; can cause serious side<br />effects. Some of these serious side effects can happen<br />at the same time and could result in death. If you<br />develop any of the following serious side effects, get<br />medical help right away. Talk with your healthcare<br />provider about whether you should continue to take<br />Noroxin&reg;.<br />Tendon rupture or swelling of the tendon<br />(tendinitis):<br />Tendon problems can happen in people of all ages</strong></p><p><strong>who take Noroxin&reg;. Tendons are tough cords of<br />tissue that connect muscle to bones. Symptoms of<br />tendon problems may include: Pain, swelling, tears<br />and inflammation of tendons including the back of<br />the ankle (Achilles), shoulder, hand, or other tendon<br />sites.<br />The risk of getting tendon problems while you take<br />Noroxin&reg; is higher if you:<br /> are over 60 years of age<br /> are taking steroids (corticosteroids)<br /> have had a kidney, heart or lung transplant<br />Tendon problems can happen in people who do not<br />have the above risk factors when they take<br />Noroxin&reg;. Other reasons that can increase your risk<br />of tendon problems can include:<br /> physical activity or exercise<br /> kidney failure<br /> tendon problems in the past, such as in<br />people with rheumatoid arthritis (RA)<br />Stop taking Noroxin&reg; immediately and get medical<br />help right away at the first sign of tendon pain,<br />swelling or inflammation.<br />Stop taking Noroxin&reg; until tendinitis or tendon<br />rupture has been ruled out by your healthcare<br />provider. Avoid exercise and using the affected area.<br />The most common area of pain and swelling is the<br />Achilles tendon at the back of your ankle. This can<br />also happen with other tendons.<br />Talk to your healthcare provider about the risk of<br />tendon rupture with continued use of Noroxin&reg;. You<br />may need a different antibiotic that is not a<br />fluoroquinolone to treat your infection.<br />Tendon rupture can happen while you are taking or<br />after you have finished taking Noroxin&reg;. Tendon<br />ruptures can happen within hours or days of taking<br />Noroxin&reg;, and have happened up to several months<br />after patients have finished taking their<br />fluoroquinolone.<br />Get medical help right away if you get any of the<br />following signs or symptoms of a tendon rupture:<br /> hear or feel a snap or pop in a tendon<br />area<br /> bruising right after an incident in a<br />tendon area<br /> unable to move the affected area or bear<br />weight&nbsp;Changes in sensation and possible nerve damage<br />(Peripheral Neuropathy):<br />Damage to the nerves in arms, hands, legs, or feet.<br />Stop taking Noroxin&reg; immediately and talk to your<br />healthcare provider right away if you get any of the<br />following symptoms in your arms, hands, legs, or feet:<br />pain, numbness, burning, weakness, tingling.<br />Noroxin&reg; may need to be stopped to prevent<br />permanent nerve damage.<br />Central Nervous System (CNS) effects:<br />Seizures have been reported in people who take<br />fluoroquinolone including Noroxin&reg;. Tell your<br />healthcare provider if you have a history of seizures<br />before you start taking Noroxin&reg;. CNS side effects<br />may happen as soon as after taking the first dose of<br />Noroxin&reg;.<br />Stop taking Noroxin&reg; immediately and talk to your<br />healthcare provider right away if you get any of these<br />side effects, or other changes in mood or behavior:<br />- Seizures<br />- trouble sleeping; feel lightheaded or dizzy<br />- hear voices, see things, or sense things,<br />nightmares that are not there (hallucinations)<br />- feel restless, feel anxious or nervous, confusion<br />- feel more suspicious (paranoia)<br />- tremors<br />- suicidal thoughts or acts<br />- headaches that will not go away, with or without<br />blurred vision<br />- depression<br />Worsening of myasthenia gravis (a disease which<br />causes muscle weakness)<br />Fluoroquinolones like Noroxin&reg; may cause worsening<br />of myasthenia gravis symptoms, including muscle<br />weakness and breathing problems. Tell your<br />healthcare provider if you have a history of<br />myasthenia gravis before you start taking Noroxin&reg;.<br />Call your healthcare provider right away if you have<br />any worsening muscle weakness or breathing<br />problems.</strong></p><p><strong>Like all medicines, Noroxin&reg; can cause side effects,<br />although not everybody gets them. Please see<br />&ldquo;Serious Adverse Events&rdquo; for some adverse events.<br />Other serious side effects of Noroxin&reg; include:<br />Serious allergic reactions. Allergic reaction can<br />happen in people who take fluoroquinolones,<br />including Noroxin&reg; even after only one dose. Stop<br />taking Noroxin&reg; and get emergency medical help<br />right away if you get any of the following symptoms<br />of a severe allergic reaction:<br />- hives<br />- trouble breathing or swallowing<br />- swelling of the lips, tongue, face<br />- throat tightness, hoarseness<br />- rapid heartbeat<br />- faint<br />- yellowing of the skin or eyes. Stop takin<br />Noroxin&reg; and tell your healthcare provider<br />right away if you get yellowing of your skin or<br />white part of your eyes, of if you have dark<br />urine. These can be signs of a serious reaction<br />(a liver problem).<br /> Skin Rash. Skin rash may happen in people taking<br />Noroxin&reg;, even after only one dose. Stop taking<br />Noroxin&reg; at the first sign of a skin rash and call<br />your healthcare provider.</strong></p><p><strong>Serious heart rhythm changes (QTc prolongation<br />and torsade de pointes). Tell your healthcare<br />provider right away if you have a change in your<br />heart beat (a fast or irregular heartbeat), or if you<br />faint. Noroxin&reg; may cause a rare heart problem<br />known as prolongation of the QTc interval. The<br />chances of this happening are higher in people:<br />- who are elderly;<br />- with a family history of prolonged QTc<br />interval;<br />- with low blood potassium (hypokalemia);<br />- who take certain medicines to control heart<br />rhythm (antiarrhythmics)<br /> Intestine Infection (Pseudomembranous colitis).<br />Pseudomembranous colitis can happen with most<br />antibiotics, including Noroxin&reg;. Call your<br />healthcare provider right away if you get watery<br />diarrhea, diarrhea that does not go away, or<br />bloody stools. Pseudomembranous colitis can<br />happen 2 or more months after you have finished<br />your antibiotic.<br /> Low blood sugar (hypoglycemia). People taking<br />Noroxin&reg; and other fluoroquinolone medicines<br />with the oral anti-diabetes medicine glyburide<br />can get low blood sugar (hypoglycemia) which<br />can sometimes be severe. Tell your healthcare<br />provider if you get low blood sugar while taking<br />Noroxin&reg;.<br /> Sensitivity to sunlight (photosensitivity)<br />The most common side effects of Noroxin include:<br />- Dizziness, headache<br />- weakness<br />- Nausea, diarrhea, heartburn, stomach<br />cramping<br />- Changes in certain liver function tests<br />Other side effects:<br />- rhabdomyolysis (breakdown of the muscle<br />tissue with muscle pain)<br />- anemia (paleness and tiredness), sometimes<br />associated with Glucose-6-<br />phosphatedehydrogenase deficiency, due to a<br />red cell loss<br />- tiredness, changes of mood, a tingling<br />sensation, sleeplessness, sleep disturbances,<br />depression, feeling of anxiety, restlessness,<br />irritability, exaggerated sense of well-being,<br />disorientation, hallucinations, confusion<br />- visual disturbance, increased production of<br />tears, ringing in the ears<br />- bleeding into the skin with inflammation of<br />blood vessels.</strong></p><p><strong>inflammation of the pancreas (symptoms<br />include abdominal pain, fever, being sick)<br />- loss of appetite<br />- inflammation of the kidneys (symptoms may<br />include blood in the urine, decreased urine)<br />- vaginal thrush (itching, soreness or burning of<br />the vagina)<br />- reduced number of white blood cells<br />&ldquo;leucocytes&ldquo;[leucopenia] or<br />&ldquo;neutrophils&rdquo;[neutropenia], increased<br />number of certain white blood cells<br />&ldquo;eosinophils&rdquo; [eosinophilia], increased<br />frequency of infections<br />- reduced number of blood platelets<br />[thrombocytopenia], reduced volume of the<br />red blood cells in the blood [hematocrit],<br />reduced blood clotting ability, which may<br />cause prolonged bleeding after injury<br />- increased liver enzymes<br />These are not all the possible side effects of<br />NOROXIN. Tell your healthcare provider about any<br />side effect that bothers you or that does not go away.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not store above 30&deg;C.<br />Store in the original package.<br />Do not use Noroxin&reg; tablets after the expiry date<br />stated on the carton and the blisters. The expiry date<br />refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Noroxin&reg; film-coated tablets contain 400 mg of<br />norfloxacin.<br />Excipients: Microcrystalline cellulose, croscarmellose<br />sodium, magnesium stearate,<br />hydroxypropylmethylcellulose, hydroxypropylcellulose,<br />titanium dioxide, carnauba wax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Noroxin® tablets are white, film-coated, oval-shaped
biconvex tablets, one side scored, the other engraved
‘ALG N400’.
Noroxin® is available in packs of 14 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Final Batch<br />Releaser:<br />ALGORITHM S.A.L. Zouk Mosbeh, Lebanon.<br />Manufacturer:<br />ALGORITHM S.A.L. Zouk Mosbeh, Lebanon.<br />&reg;Registered trademark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                .07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي نوروكسينم إلى مجموعة من المضادات الحيوية تُسمّى كينولونات. يُستعمل لعلاج بعض<br />حالات العدوى البكتيريّة مثل:<br />- التهابات المسالك البوليّة )التهابات المسالك البوليّة غير المعقّدة التي تتضمّن التهاب المثانة<br />والتهابات المسالك البوليّة المعقّدة(<br />- الأمراض المنقولة جنسيًا )داء السيلان غير المعقّد في الإحليل وعنق الرحم بسبب النيسرية البنية(<br />- التهاب البروستات )بسبب الإشريكيّة القولونيّة(<br />إنّ العدوى الأكثر شيوعًا لدى النساء تصيب المثانة، وتعرف بالتهاب المثانة. أما بالنسبة إلى<br />الرجال، فقد تشمل العدوى البروستات وهو ما يعرف بالتهاب البروستات. ولدى كلّ من الرجال<br />والنساء، قد تنتقل البكتيريا إلى الأعلى وتصيب الكليتين.<br />قد تتضمّن عوارض التهاب المسالك البوليّة حاجة ملحّة إلى التبوّل المتكرّر وبكميّات صغيرة،<br />وإحساسًا مؤلمًا بالحريق عند التبوّل. يجب معالجة التهابات المسالك البوليّة لتفادي إصابة الكليتين.<br />يعمل نوروكسينم عن طريق قتل البكتيريا التي تسبّب العدوى. قد يكون طبيبك وصف لك<br />نوروكسينم لسببٍ آخر.<br />لا ينبغي استعمال نوروكسينم لدى المرضى المصابين بتفاقم حادّ في التهاب الشعب الهوائيّة المزمن<br />وبالتهاب المثانة الحاد غير المعقّد وبالتهابات الجيوب الأنفيّة، في حال وجود خيارات علاجيّة<br />أخرى.<br />لا ينبغي استعمال نوروكسينم كالخيار الأوّل من الأدوية المضادة للبكتيريا لعلاج التهابات الجهاز<br />التنفّسي السفلي التي يسبّبها نوع معيّن من البكتيريا المسمّاة العقديّة الرئويّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم أقراص نوروكسينم لدى الأطفال دون سن 18 سنة. فإن احتمال الإصابة بمشاكل العظام<br />والمفاصل لدى الأطفال كبير جداً في حال تناولهم نوروكسينم.<br />لا تأخذ نوروكسينم إذا:<br />- كنت تعاني من حساسيّة ضد نوروكسينم، أو ضد مضادات أخرى من فئة الكينولونات أو ضد أيّ<br />من المركّبات المذكورة في نهاية هذه النشرة )راجع القسم 7(. قد تشمل أعراض ردّ الفعل التحسسي<br />تجاه نوروكسينم الحكّة والشرى وتورّم الوجه و/أو الشفتين و/أو اللسان و/أو الحلق )ممّا قد يسبّب<br />صعوبة في التنفّس أو البلع(، أو ألم في العضلات أو وجع عند لمسها، أو ألم في المفاصل.<br />- كنتِ حاملاً أو كنتِ ترضعين.<br />- أصبتَ بألم أو التهاب أو تمزّق في الأوتار بعد أخذ مضادات حيويّة من فئة الكينولونات.</p><p dir="RTL">إذا لم تكن متأكّدًا مما إذا كان عليك البدء بأخذ نوروكسينم، راجع طبيبك.<br />إعتمد عناية خاصة مع نوروكسينم<br />أخبر طبيبك عن حالتك الصحية، وكذلك إذا:<br />- كانت لديك مشاكل في الأوتار<br />- كنتَ تعاني من الوهن العضلي الوبيل وهو مرض يسبّب ضعفًا في العضلات.<br />- كنتَ تعاني من مشاكل في الجهاز العصبي المركزي )مثل الصرع(.<br />- كانت لديك مشاكل في الأعصاب: لا ينبغي استعمال نوروكسينم لدى المرضى الذين أصيبوا في<br />السابق بمشكلة في الأعصاب تُسمّى الاعتلال العصبي المحيطي.<br />- كنت تعاني أنت أو أيّ فرد من عائلتك من عدم انتظام ضربات القلب، بخاصة حالة تسمّى &ldquo;<br />استطالة فترة .&rdquo;QT<br />- كنت تعاني من انخفاض في البوتاسيوم )نقص بوتاسيوم الدم(.<br />- كنت تعاني من بطء في ضربات القلب.<br />- كان لديك تاريخ من نوبات الصرع.<br />- كنت تعاني من مشاكل في الكلى. قد تحتاج إلى جرعة أقل من نوروكسينم إذا كانت الكليتان لا<br />تعملان بشكلٍ جيّد.<br />- كنت تعاني من التهاب المفاصل الروماتويدي أو أي مشاكل سابقة في المفاصل )تاريخ عائلي<br />لاضطرابات النسيج الضام، مرض بهجت(<br />- كنتِ حاملاً او تخططين لتصبحي حاملاً. لا يزال غير معروف ما إذا كان نوروكسينم ضاراً<br />للجنين.<br />- كنتِ ترضعين أو تخططين لترضعي. من غير المعروف ما إذا كان نوروكسينم ينتقل إلى حليب<br />الأم. يجب أن تقرري أنتِ وطبيبك ما إذا كنتِ ستأخذينه أو ترضعين.<br />- كنت تعاني من اضطراب نفسي وهلوسة و/أو ارتباك<br />- كنت تعاني أنت أو أيّ فرد من عائلتك من اضطراب نقص يصبح فيه المرضى مصابين بفقر دم<br />بعد أخذ بعض الأدوية )نقص في نازعة هدروجين غلوكوز- 6-فوسفات .)PD-6-G<br />- تم تشخيص إصابتك بتضخم أو &ldquo;انتفاخ&rdquo; أحد الأوعية الدموية الكبيرة )تمدد الأوعية الدموية<br />الأبهري أو تمدد الأوعية الدموية الطرفية(.<br />- تعرضت لنوبة تسلخ الأبهر )تمزق في جدار الشريان الأبهر(<br />- كان هناك خطر الإصابة بارتجاع صمام القلب/قصور صمام القلب/وتسلّخ الأبهر )تاريخ عائلي<br />لاضطرابات النسيج الضام، مرض بهجت، ارتفاع ضغط الدم(<br />أسرع إلى المستشفى أو أطلب المساعدة الطبية، إذا:<br />- شعرتَ بضيق مفاجئ في التنفس وخفقان القلب وتطور احتباس الماء في البطن أو الأطراف<br />السفلية، اذهب فورًا إلى غرفة الطوارئ واطلب المساعدة الطبية.<br />- ضعُفَ بصرك وإذا شعرتَ بأي مشكلة أخرى في عينيك.<br />أخذ نوروكسينم مع أدوية أخرى<br />يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول حاليًا أو سبق وتناولت مؤخّرًا أيّ أدوية أخرى بما<br />فيها تلك التي حصلت عليها بموجب أو بدون وصفة طبيّة، بالإضافة إلى الفيتامينات والمكمّلات<br />العشبية والغذائية. وذلك لأنّه يمكن لنوروكسينم أن يؤثّر على مفعول بعض الأدوية الأخرى،<br />والعكس صحيح مما قد يسبب بعض الأعراض الجانبية، نذكر منها:<br />- نيتروفورانتوين، وهو مضاد حيويّ آخر يُستعمل لعلاج التهابات المسالك البوليّة.<br />- العقاقير غير الستيرويدية المضادة للالتهابات ) NSAIDs (، العديد من الأدوية المسكنة للألم<br />هي مضادات الالتهاب غير الستيرويدية. قد يؤدي تناول مضادات الالتهاب غير الستيروئيدية أثناء<br />تناول نوروكسينم أو الفلوروكينولونات الأخرى إلى زيادة خطر تعرضك لتأثيرات الجهاز العصبي<br />المركزي ونوبات الصرع.<br />- غليبوريد، جليبنكلاميد، وهو دواء يستخدم لعلاج مرض السكري<br />- مميعات الدم )وارفارين، كومادين(<br />- الأدوية المستخدمة للتحكم في معدل ضربات القلب أو الإيقاع )مضاد لاضطراب النظم( مثل<br />سوتالول وأميودارون وكينيدين وبروكاييناميد<br />- مضادات الذهان وهي مجموعة من الأدوية تُستعمل لعلاج بعض الحالات العقليّة والعاطفيّة<br />- مضادات الاكتئاب الثلاثيّة الحلقات وهي مجموعة من الأدوية تُستعمل لعلاج الاكتئاب مثل<br />الأميتريبتيلين والنورتريبتيلين.<br />- الاريثروميسين، وهو نوع آخر من المضادات الحيوية يستخدم لعلاج العدوى وتجنّب الإصابة بها<br />في بعض الحالات.<br />- البروبينسيد، وهو دواء يستخدم لعلاج النقرس<br />- السيكلوسبورين وهو دواء يُستعمل بصورة شائعة لدى المرضى الذين تلقّوا زرع عضو<br />- المنتجات التي تحتوي على الكافيين<br />- بعض الأدوية التي يتم استقلابها بواسطة إنزيم معين في الكبد مثل: كافيين، كلوزابين، روبينيرول،<br />تاكرين، ثيوفيلين، تيزانيدين<br />- الثيوفيلين، وهو دواء يستخدم لعلاج الربو<br />- سيسابريد، وهو دواء يستخدم لعلاج الانزعاج الناتج عن تدفق حمض المعدة في الاتجاه الخاطئ<br />إلى المريء )ويسمى أيضًا أنبوب الطعام(<br />- قد تتأثّر هذه الأدوية بنوروكسينم أو قد تؤثّر على مفعوله. عليك أن تأخذ نوروكسينم سواء قبل</p><p dir="RTL">ساعتين أو بعد ساعتين من أخذ أيّ من هذه الأدوية:<br />- مضادات الحموضة المستعملة لعسر الهضم<br />- سكرالفات، وهو دواء يُستعمل لعلاج قرحة المعدة<br />- الديدانوزين، وهو دواء يُستعمل لعلاج عدوى فيروس نقص المناعة البشريّة<br />- مكمّلات الحديد أو الزنك، والفيتامينات المتعددة التي تحتوي عليها<br />راجع طبيبك إذا لم تكن متأكدًا مما إذا كان الدواء الخاص بك مذكوراً أعلاه.<br />تعرّف على الأدوية التي تتناولها. احتفظ بقائمة الأدوية الخاصة بك وأظهرها لطبيبك أو الصيدلي<br />عندما تحصل على دواء جديد.<br />الحمل، الرضاعة والخصوبة<br />يجب عليكِ أن تُعلمي طبيبك إذا كنتِ حاملاً أو إذا كنتِ تخططين للحمل أو ترضعين إذ إن استعمال<br />هذا الدواء غير مستحسن في هذه الحالات.<br />القيادة واستعمال الآلات<br />يرجى تفادي القيادة أو تشغيل الآلات أو القيام بأي أنشطة أخرى تتطلب اليقظة العقلية أو التنسيق<br />إلى أن تعرف كيف سيؤثر نوروكسينم عليك. فقد تشعر بدوار بعد تناول نوروكسينم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ نوروكسينم وفقاً لتعليمات طبيبك تمامًا. يجب عليك التحقق مع طبيبك أو الصيدلي إذا لم تكن<br />متأكّدًا.<br />كيف يُؤخذ هذا الدواء:<br />- إبلع الأقراص كاملة مع كوب من الماء. اشرب الكثير من السوائل أثناء تناول نوروكسينم.<br />- نوروكسينم عادة ما يتم تناوله كل 12 ساعة للمرضى ذوي الكلى التي تعمل بانتظام.<br />- تناول نوروكسينم على معدة فارغة قبل الطعام بساعة على الأقل أو بعد الطعام بساعتين.<br />ما هو مقدار الجرعة:<br />- خذ نوروكسينم عندما يصفه لك طبيبك فقط.<br />- سوف يحدّد لك طبيبك عدد الأقراص التي عليك أخذها كلّ يوم.<br />- تبلغ الجرعة العاديّة من نوروكسينم قرصًا واحدًا ) 400 ملغرام من النورفلوكساسين( مرّتين في<br />اليوم للمرضى ذوي الكلى التي تعمل بانتظام.<br />في حالة المرضى الذين يعانون من مشاكل في الكلى:<br />- إذا كنت تعاني من قصور كلوي شديد، فقد يقوم طبيبك بتعديل جرعتك.<br />الجرعة الموصى بها هي قرص واحد ) 400 ملغرام نورفلوكساسين( مرة واحدة يومياً.<br />يُفضّل أخذ الأقراص في الصباح والمساء. إذا كنت تأخذ جرعة يوميّة واحدة فقط، خذها دائمًا في<br />الوقت ذاته كلّ يوم.<br />ما هي مدّة العلاج بنوروكسينم<br />استمرّ بأخذ نوروكسينم حتّى تُنهي العلبة أو وفقًا لتعليمات طبيبك.<br />- لعلاج التهابات المسالك البوليّة: قد تتراوح مدّة العلاج بين ثلاثة وعشرة أيّام.<br />- للمساعدة على تفادي عودة التهابات المسالك البوليّة: قد تحتاج إلى أخذ نوروكسينم لغاية 12<br />أسبوعًا.<br />لا تفوّت أيّ جرعات من نوروكسينم ولا تتوقّف عن أخذه حتّى ولو بدأت تشعر يتحسّن، حتّى تُنهي<br />العلاج الموصوف لك إلاّ:<br />- إذا كنت تعاني من مشاكل في الأعصاب )الأعراض الجانبيّة الخطيرة(<br />- إذا كنت تعاني من مشاكل في الجهاز العصبي المركزي )الأعراض الجانبيّة الخطيرة(<br />إذا أخذت كميّة من نوروكسينم أكثر من التي يجب عليك أخذها<br />أخبر طبيبك أو اذهب مباشرة إلى أقرب مستشفى. لا تقد السيّارة بنفسك بل اطلب من أحد آخر أن<br />يأخذك أو اطلب سيّارة إسعاف.<br />خذ علبة الدواء معك لكي يعرف الطبيب ماذا تناولت.<br />-إذا نسيت أخذ نوروكسينم<br />-إذا فوّت جرعة، خذ جرعتك العاديّة حالما تتذكّر.<br />-إذا حان وقت أخذ جرعتك التالية، فوّت الجرعة التي نسيتها واستمرّ في أخذ جرعاتك كالمعتاد.<br />-لا تأخذ جرعة مضاعفة للتعويض عن القرص الذي نسيت أخذه.<br />أثناء تناول نوروكسينم، عليك تجنّب:<br />- المصابيح الشمسية وأسرّة التسمير وحاول أن تحدّ من الوقت الذي تقضيه في الشمس. يمكن أن<br />يجعل نوروكسينم بشرتك حساسة )حساسية الضوء(. قد تصاب بحروق بليغة أو وقد تظهر على<br />بشرتك البثور أو التورم. إذا ظهرت لديك أي من هذه الأعراض أثناء تناول نوروكسينم، راجع<br />طبيبك على الفور. يجب عليك استخدام واقٍ من الشمس وارتداء قبعة وملابس تغطي بشرتك إذا<br />كنتَ تتعرّض لأشعة الشمس.<br />إذا كانت لديك أيّ أسئلة أخرى حول استعمال هذا الدواء، اطرحها على الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1. الأعراض الجانبيّة الخطيرة<br />ينتمي نوروكسينم إلى فئة من المضادات الحيويّة تُسمّى الفلوروكينولونات. يمكن أن يسبّب<br />نوروكسينم أعراض جانبية خطيرة. ومن الممكن أن تحصل بعض هذه الأعراض الجانبيّة في<br />الوقت ذاته فتسبّب الوفاة. لذا، إذا أُصبتَ بأيّ من الأعراض الجانبيّة الخطيرة التالية، أطلب المساعدة<br />الطبيّة على الفور. اسأل طبيبك إذا كان يجب عليك أن تواصل أخذ نوروكسينم .<br />تمزّق الوتر أو تورّم الوتر )التهاب الوتر(<br />يمكن أن يتعرّض الأشخاص الذين يأخذون نوروكسينم من الأعمار كافة لمشاكل في الأوتار.<br />الأوتار هي حبال صلبة من الأنسجة تربط ما بين العضلات والعظام. يمكن أن تتضمّن عوارض<br />مشاكل الأوتار ما يلي: ألم، تورّم، تمزّق والتهاب الأوتار بما في ذلك في الجزء الخلفي من الكاحل<br />)العرقوب( أو الكتف أو اليد أو مواقع الأوتار الأخرى.<br />يكون خطر إصابتك بمشاكل في الأوتار وأنت تأخذ نوروكسينم أعلى إذا:<br />- قد تجاوزت ال 60 سنة<br />- كنتَ تتناول الستيرويدات )الكورتيكوستيرويدات(<br />- خضعت لعملية زرع كلية أو قلب أو رئة<br />وكذلك، قد يعاني الأشخاص من مشاكل الأوتار عند تناولهم نوروكسينم حتى ولو أنهم لا يُظهرون<br />أي من عوامل الخطر المذكورة أعلاه. يمكن أن تشمل الأسباب الأخرى التي يمكن أن تزيد من<br />خطر الإصابة بمشاكل الأوتار ما يلي:<br />- النشاط البدني أو الرياضة<br />- الفشل الكلوي<br />- مشاكل في الأوتار في الماضي، مثل الأشخاص المصابين بالتهاب المفاصل الروماتويدي.<br />توقّف عن أخذ نوروكسينم على الفور واطلب المساعدة الطبيّة الطارئة عند الإشارة الأولى لألم أو<br />تورّم أو التهاب في الأوتار.<br />توقّف عن أخذ نوروكسينم إلى أن يستبعد طبيبك احتمال إصابتك بالتهاب أو تمزّق في الأوتار.<br />تجنّب ممارسة الرياضة واستعمال المنطقة المصابة. إنّ أكثر مناطق الألم والتورم شيوعًا هي وتر<br />العرقوب في الجزء الخلفي من الكاحل. يمكن أن يحدث هذا أيضًا مع أوتار أخرى.<br />تحدّث إلى طبيبك حول خطر تمزّق الوتر مع الاستعمال المستمرّ لنوروكسينم. فقد تحتاج إلى مضاد<br />حيويّ مختلف ولا ينتمي إلى فئة الفلوروكينولونات لعلاج الحالة التي تعاني منها.<br />يمكن أن يحصل تمزّق الوتر في خلال فترة علاجك بنوروكسينم أو بعد الانتهاء من أخذه. يمكن<br />أن تحصل تمزّقات الأوتار في غضون ساعات أو أيّام بعد أخذ نوروكسينم، أو بعد عدة أشهر من<br />الإنتهاء من أخذ الفلوروكينولون.<br />أطلب المساعدة الطبيّة على الفور إذا ظهرت إحدى الإشارات أو العوارض التالية التي تدلّ على<br />وجود تمزّق في الوتر:<br />- سماع صوت طقطقة أو قرقعة أو الشعور به في منطقة الوتر.<br />- ازرقاق بعد التعرّض لحادث في منطقة الوتر.<br />- عدم القدرة على تحريك المنطقة المصابة أو على حمل الأوزان.</strong></p><p dir="RTL"><strong>تغييرات في الإحساس وتضرّر محتمل في الأعصاب )الاعتلال العصبي المحيطي(<br />ضرر في أعصاب الذراعين أو اليدين أو الساقين.<br />توقّف عن أخذ نوروكسينم على الفور وتحدّث إلى طبيبك في الحال ظهور أيّ من العوارض التالية<br />في الذراعين أو اليدين أو الساقين: ألم، تخدّر، حريق، ضعف، تنميل.<br />قد يكون من الضروري التوقّف عن أخذ نوروكسينم لمنع حصول ضرر دائم في الأعصاب.<br />الآثار على الجهاز العصبي المركزي:<br />أفادت بعض التقارير أن الأشخاص الذين يتناولون الفلوروكينولونات بما في ذلك نوروكسينم<br />يتعرّضون لنوبات صرع.أخبر طبيبك إذا أصبت في السابق بنوبات صرع قبل أن تبدأ بتناول<br />نوروكسينم. قد تظهر الأعراض الجانبية في الجهاز العصبي المركزي بعد أخذ الجرعة الأولى من<br />نوروكسينم مباشرة.<br />توقف عن تناول نوروكسينم على الفور وأبلغ طبيبك إذا ظهرت لديك أيّ من الآعراض الجانبيّة هذه<br />أو لاحظتَ تغييرات أخرى في المزاج أو السلوك:<br />- نوبات صرع<br />- مشاكل في النوم<br />- دوار<br />- سماع أصوات أو رؤية أشياء أو الشعور بأشياء<br />- كوابيس غير موجودة )هلوسات(<br />- شعور بالتململ، القلق، أو العصبية<br />- تزايد الشعور بالريبة )جنون الارتياب(<br />- ارتعاش<br />- أفكار أو تصرّفات انتحاريّة<br />- أوجاع في الرأس لا تتوقّف مع أو بدون تشوّش في الرؤية<br />- اكتئاب<br />تفاقم الوهن العضلي الوبيل )مرض يسبّب ضعفًا في العضلات(:<br />أدوية الفلوروكينولون مثل نوروكسينم قد تُفاقم عوارض الوهن العضلي الوبيل بما فيها الضعف<br />العضلي ومشاكل التنفّس. راجع طبيبك إذا عانيت في السابق من الوهن العضلي الوبيل قبل أن تبدأ<br />بأخذ نوروكسينم. اتصل بطبيبك على الفور إذا أصبتَ بأيّ ضعف في العضلات أو بمشاكل في<br />التنفّس.</strong></p><p dir="RTL">مثل سائرالأدوية، يمكن أن يسبّب نوروكسينم أعراضاً جانبيّة لا تحدث مع المرضى كلّهم. يرجى<br />قراءة &ldquo;الأحداث السلبية الخطيرة&rdquo; للإطلاع على بعض الأحداث السلبية التي قد تنشأ.<br />تشمل الأعراض الجانبية الخطيرة الأخرى لنوروكسينم ما يلي:<br />&bull; ردود فعل تحسسية خطيرة. يمكن أن يحدث رد فعل تحسسي لدى الأشخاص الذين يتناولون<br />الفلوروكينولونات، بما في ذلك نوروكسينم حتى بعد جرعة واحدة فقط. توقف عن تناول<br />نوروكسينم واطلب مساعدة طبية طارئة إذا ظهرت عليك أي من الأعراض التالية لرد فعل تحسسي<br />شديد:<br />- الشرى<br />- صعوبة في التنفس أو البلع<br />- انتفاخ الشفتين واللسان والوجه<br />- ضيق الحلق، بحة في الصوت<br />- ضربات قلب سريعة<br />- إغماء<br />- اصفرار الجلد أو العينين. توقف عن تناول نوروكسينم وأخبر طبيبك إذا كنت تعاني من اصفرار<br />بشرتك أو جزء أبيض من عينيك، أو إذا كان البول داكن اللون. يمكن أن تكون هذه علامات لرد<br />فعل خطير )مشكلة في الكبد(.<br />&bull;الطفح الجلدي. قد يحدث طفح جلدي لدى الأشخاص الذين يتناولون نوروكسينم، حتى بعد جرعة<br />واحدة فقط. توقف عن تناول نوروكسينم عند ظهور أول بادرة لطفح جلدي واتصل بطبيبك.<br />تغيرات خطيرة في نظم القلب )استطالة فترة QT وتورساد دي بوان(. أخبر طبيبك على الفور<br />إذا لاحظتَ تغييراً في ضربات قلبك )ضربات قلب سريعة أو غير منتظمة(، أو إذا فقدت الوعي.<br />قد يسبب نوروكسينم مشكلة قلبية نادرة تعرف باسم استطالة فترة QT . يمكن أن تسبب هذه<br />الحالة ضربات قلب غير طبيعية وقد تكون خطيرة جداً. إن احتمال الإصابة بذلك يكون كبيراً لدى<br />الأشخاص الذين:<br />هم من كبار السن.<br />- لديهم تاريخ عائلي من الإصابة بفترات QT الطويلة؛<br />- يعانون من انخفاض نسبة البوتاسيوم في الدم )نقص بوتاسيوم الدم(؛<br />- يتناولون أدوية معينة للتحكم بنظم القلب )مضادات اضطراب النظم(.<br />&bull; التهاب الأمعاء )التهاب القولون الغشائي الكاذب(. يمكن أن يحدث التهاب القولون الغشائي الكاذب<br />بسبب استخدام معظم المضادات الحيوية، بما في ذلك نوروكسينم. اتصل بطبيبك على الفور إذا<br />أصبت بإسهال مائي أو إسهال لا يزول أو براز دموي. قد تُصاب بتقلصات في المعدة وبالحمى.<br />يمكن أن تُصابَ بالتهاب القولون الغشائي الكاذب بعد شهرين أو أكثر من انتهاء تناول المضاد<br />الحيوي.<br />&bull; انخفاض نسبة السكر في الدم. يمكن للأشخاص الذين يتناولون نوروكسينم وأدوية الفلوروكينولون<br />الأخرى مع دواء الغليبوريد الفموي المضاد للسكري أن يصابوا بانخفاض نسبة السكر في الدم<br />)نقص السكر في الدم( والذي قد أن يكون خطيراً في بعض الأحيان. يرجى مراجعة الطبيب في<br />حال انخفضت نسبة السكر في الدم أثناء تناول نوروكسينم. قد يكون من الضروري تغيير المضاد<br />الحيوي الذي تتناوله.<br />&bull; الحساسية لأشعة الشمس )حساسية الضوء(<br />&bull;الأعراض الجانبيّة الأكثر شيوعًا لنوروكسينم:<br />- دوار، غثيان، إسهال، حرقة المعدة، صداع، تشنّج في المعدة )في البطن(، ضعف، تغييرات في<br />بعض اختبارات وظائف الكبد<br />أعراض جانبية أخرى:<br />- انحلال الربيدات )انهيار الأنسجة العضلية مع آلام العضلات(<br />- فقر الدم )الشحوب والتعب(، والذي يرتبط أحيانًا بنقص نازعة الجلوكوز 6 فوسفات هيدروجيناز،<br />بسبب فقدان خلايا الدم الحمراء<br />- التعب، تغيرات المزاج، الإحساس بالوخز، الأرق، اضطرابات النوم، الاكتئاب، الشعور بالقلق،<br />التململ، التهيج، الإحساس المبالغ فيه بالرفاهية، الإرتباك، الهلوسة.<br />- إضطراب بصري، زيادة إفراز الدموع،<br />- طنين في الأذنين.<br />- نزيف في الجلد مع التهاب الأوعية الدموية.<br />- التهاب البنكرياس )تشمل الأعراض آلام البطن والحمى والمرض(.<br />- فقدان الشهية.<br />- التهاب الكلى )قد تشمل الأعراض وجود دم في البول، نقص في البول(.<br />- القلاع المهبلي )حكة أو ألم أو حرقان في المهبل(.<br />- انخفاض عدد خلايا الدم البيضاء &ldquo;الكريات البيض&rdquo; أو &ldquo;العدلات&rdquo;، وزيادة عدد خلايا الدم البيضاء<br />المعينة &ldquo;الحمضات&rdquo; ]فرط اليوزينيات[، مما قد يسبب التهاب الحلق والفم، وزيادة وتيرة الالتهابات.<br />- انخفاض عدد الصفائح الدموية، وانخفاض حجم خلايا الدم الحمراء في الدم ]الهيماتوكريت[،<br />انخفاض القدرة على تخثر الدم، مما قد يؤدي إلى نزيف طويل الأمد بعد الإصابة.<br />- زيادة إنزيمات الكبد.</p><p dir="RTL">&bull; هذه ليست كل الأعراض الجانبية المحتملة لنوروكسينم. أبلغ طبيبك عن أي أثر جانبي يزعجك<br />أو لا يزول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفظ بعيدًا عن متناول الأطفال ونظرهم.<br />يُحفظ في درجة حرارة لا تتعّدى 30 درجة مئويّة.<br />يُحفظ الدواء في علبته الأصليّة.<br />لا تستعمل أقراص نوروكسينم بعد انقضاء تاريخ الصلاحيّة المذكور على علبة الكرتون والظروف.<br />يشير تاريخ انتهاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحتوي أقراص نوروكسينم المطلّية الغشاء على 400 ملغرام من النورفلوكساسين.<br />السواغات: سلولوز دقيق البلوريّة، كروسكارميلوز الصوديوم، ستيارات المغنيزيوم،<br />هيدروكسيبروبيل ميثيل سلولوز، هيدروكسيبروبيل سلولوز، ثاني أكسيد التيتانيوم، شمع الكرنوبا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص نوروكسينم بيضاء اللون، مطليّة الغشاء، بيضاويّة الشكل وثنائيّة التحدّب، جهة منها محززة<br />والجهة الأخرى محفور عليها: .ALG N400<br />يأتي نوروكسينم في علب تحتوي على 14 قرصًا.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق والمصنع المسؤول عن تحرير الصنف:<br />ألغوريتم ش.م.ل. ذوق مصبح، لبنان<br />الشركة المصنّعة<br />ألغوريتم ش.م.ل. ذوق مصبح، لبنان<br />م ماركة مسجلة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            .07/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Noroxin® 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of Noroxin® contains 400 mg norfloxacin. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Noroxin&reg; is indicated for the treatment of adults with upper and lower tract infections, specifically<br />complicated and uncomplicated cystitis, pyelitis and pyelonephritis the following infections caused<br />by susceptible strains of the designated microorganisms:<br />Escherichia coli<br />Klebsiella pneumonia<br />Unspecified Klebsiella spp.<br />Unspecified Enterobacter spp.<br />Unspecified Citrobacter spp.<br />Proteus mirabilis<br />Staphylococcus aureus<br />Streptococcus faecalis<br />Pseudomonas aeruginosa<br />In cases of uncomplicated acute bacterial cystitis, limit the use of NORFLOXACIN to circumstances<br />where no other treatment options are available. A urine culture should be obtained prior to<br />Fluoroquinolones, including Noroxin&reg;, have been associated with disabling and potentially irreversible<br />serious adverse reactions that have occurred together including:<br />o Tendinitis and tendon rupture<br />o Peripheral neuropathy<br />o Central nervous system effects<br />Discontinue Noroxin&reg; immediately and avoid the use of fluoroquinolones, including Noroxin&reg;, in patients<br />who experience any of these serious adverse reactions. Fluoroquinolones, including Noroxin&reg;, may<br />exacerbate muscle weakness in patients with myasthenia gravis. Avoid Noroxin&reg; in patients with known<br />history of myasthenia gravis.<br />Because fluoroquinolones, including Noroxin&reg;, have been associated with serious adverse reactions,<br />reserve Noroxin&reg; for use in patients who have no alternative treatment options for uncomplicated<br />urinary tract infections (including cystitis).<br />treatment to ensure norfloxacin susceptibility.<br />Sexually transmitted diseases<br />The treatment of adults with gonococcal urethritis, or cervicitis due to penicillinase producing and<br />non-penicillinase producing Neisseria gonorrhoeae.<br />Prostatitis<br />Prostatitis due to Escherichia coli.<br />Limit the use of Noroxin&reg; to patients where no other treatment options exist AND where Noroxin&reg;<br />susceptibility is demonstrated, OR Noroxin&reg; susceptibility is highly likely, typically greater than or<br />equal to 95%, based on local susceptibility patterns.<br />To reduce the development of drug-resistant bacteria and maintain the effectiveness of Noroxin&reg;<br />and other antibacterial drugs, Noroxin&reg; should be used only to treat infections that are proven or<br />strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information<br />are available, they should be considered in selecting or modifying antibacterial therapy. In the<br />absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric<br />selection of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Noroxin&reg; tablets should be taken at least one hour before or at least two hours after a meal or<br />ingestion of milk and/or other dairy products. Multivitamins, other products containing iron or zinc,<br />antacids containing magnesium and aluminum, sucralfate, or didanosine, chewable/buffered<br />tablets or the pediatric powder for oral solution, should not be taken within 2 hours of<br />administration of norfloxacin.<br />Noroxin&reg; tablets should be taken with a glass of water. Patients receiving Noroxin&reg; should be well<br />hydrated.<br />Susceptibility of the causative organism to Noroxin&reg; should be tested; however, therapy may be<br />initiated before obtaining the results of these tests.<br />Normal Renal Function<br />The recommended daily dose of Noroxin&reg; is as described in the following chart:<br />Infection Description Unit Dose Frequency Duration Daily Dose<br />Urinary Tract<br />Uncomplicated UTI&#39;s<br />(cystitis) due to E. coli,<br />K. pneumoniae, or P.<br />mirabilis<br />400 mg q12h 3 days 800 mg<br />Uncomplicated<br />UTI&#39;s due to other<br />indicated organisms<br />400 mg q12h 7-10 days 800 mg<br />Complicated UTI&#39;s 400 mg q12h 10-21 days 800 mg<br />Sexually Transmitted<br />Diseases<br />Uncomplicated<br />Gonorrhea<br />800 mg single dose 1 day 800 mg<br />Prostatitis Acute or Chronic 400 mg q12h 28 days 800 mg<br />Renal impairment:<br />Noroxin&reg; may be used for the treatment of urinary tract infections in patients with renal</p><p>insufficiency who do not require hemodialysis.<br />In patients with a creatinine clearance rate of 30 mL/min/1.73 m2 or less, the recommended dosage<br />is one 400-mg tablet once daily for the duration given above. At this dosage, the urinary<br />concentration exceeds the MICs for most urinary pathogens susceptible to norfloxacin, even when<br />the creatinine clearance is less than 10 mL/min/1.73 m2.<br />When only the serum creatinine level is available, the following formula (based on sex, weight, and<br />age of the patient) may be used to convert this value into creatinine clearance. The serum<br />creatinine should represent a steady state of renal function.<br />Males: (weight in kg) &times; (140 &ndash; age)<br />(72) &times; serum creatinine (mg/100 mL)<br />Females: (0.85) &times; (above value)<br />The administration of Noroxin&reg; to anuric patients is not recommended.<br />Elderly<br />Elderly patients being treated for urinary tract infections who have a creatinine clearance of greater<br />than 30 mL/min/1.73 m2 should receive the dosages recommended under &ldquo;Normal Renal Function&rdquo;.<br />Elderly patients being treated for urinary tract infections who have a creatinine clearance of 30<br />mL/min/1.73 m2 or less should receive 400 mg once daily as recommended under &ldquo;Renal<br />Impairment&rdquo;.<br />Pediatrics<br />The safety and efficacy of Noroxin&reg; in pre-pubertal children have not been established.<br />Noroxin&reg; should be used in patients in whom epiphyseal closure has not occurred (see Warnings).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Noroxin® is contraindicated in persons with a history of hypersensitivity to Norfloxacin, to any of
this product excipients or to other quinolone antibacterial agents.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Warnings<br />Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon<br />Rupture, Peripheral Neuropathy, and neuropsychiatric effects.<br />Fluoroquinolones, including Noroxin&reg;, have been associated with disabling and potentially<br />irreversible serious adverse reactions from different body systems that can occur together in the<br />same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia,<br />myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety,<br />depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to<br />weeks after starting Noroxin&reg;. Patients of any age or without pre-existing risk factors have<br />experienced these adverse reactions. Discontinue Noroxin&reg; immediately at the first signs or<br />symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including<br />Noroxin&reg;, in patients who have experienced any of these serious adverse reactions associated with<br />fluoroquinolones.<br />Tendinopathy and Tendon Rupture:<br />Fluoroquinolones, including Noroxin&reg;, have been associated with an increased risk of tendinitis and<br />tendon rupture in all ages. This adverse reaction most frequently involves the Achilles tendon, and<br />has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and<br />other tendons. Tendinitis or tendon rupture can occur within hours or days of starting Noroxin&reg;, or<br />as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon</u></p><p><u>rupture can occur bilaterally.<br />The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in<br />patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney,<br />heart or lung transplants. Other factors that may independently increase the risk of tendon rupture<br />include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid<br />arthritis. Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who<br />do not have the above risk factors.<br />Tendon rupture can occur during or after completion of therapy cases occurring up to several months<br />after completion of therapy have been reported.<br />Discontinue Noroxin&reg; immediately if the patient experiences pain, swelling, inflammation or rupture<br />of a tendon. Avoid fluoroquinolones, including Noroxin&reg;, in patients who have a history of tendon<br />disorders or have experienced tendinitis or tendon rupture. Patients should be advised to rest at the<br />first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing<br />to a non-quinolone antimicrobial drug.<br />Exacerbation of Myasthenia Gravis:<br />Fluoroquinolones, including Noroxin&reg;, have neuromuscular blocking activity and may exacerbate<br />muscle weakness in patients with myasthenia gravis. Post-marketing serious adverse reactions,<br />including deaths and requirement for ventilatory support, have been associated with<br />fluoroquinolone use in patients with myasthenia gravis. Avoid Noroxin&reg; in patients with known<br />history of myasthenia gravis.<br />Safety in Children, Adolescents, Nursing mothers, and during Pregnancy: THE SAFETY AND<br />EFFICACY OF ORAL NORFLOXACIN IN PEDIATRIC PATIENTS, ADOLESCENTS (UNDER THE AGE OF<br />18), PREGNANT WOMEN, AND NURSING MOTHERS HAVE NOT BEEN ESTABLISHED. (See<br />PRECAUTIONS, Pediatric Use, Pregnancy, and Nursing Mothers subsections.)<br />The oral administration of single doses of norfloxacin, 6 times (the recommended human clinical dose<br />(on a mg/kg basis based on a patient weight of 50kg), caused lameness in immature dogs. Histologic<br />examination of the weight- bearing joints of these dogs revealed permanent lesions of the cartilage.<br />Other quinolones also produced erosions of the cartilage in bearing joints and other signs of<br />arthropathy in immature animals of various species.<br />Central Nervous System Effects/Disorders:<br />Fluoroquinolones, including Noroxin&reg;, have been associated with an increased risk of central nervous<br />system (CNS) effects, including convulsions, increased intracranial pressure (including pseudo tumor<br />cerebri), and toxic psychoses. Quinolones may also cause CNS stimulation which may lead to tremors,<br />restlessness, lightheadedness, confusion, and hallucinations. If these reactions occur in patients<br />receiving norfloxacin, the drug should be discontinued and appropriate measures instituted.<br />The effects of norfloxacin on brain function or on the electrical activity of the brain have not been<br />tested. Therefore, until more information becomes available, norfloxacin, like all other quinolones,<br />should be used with caution in patients with known or suspected CNS disorders, such as severe<br />cerebral arteriosclerosis, epilepsy, and other factors which predispose to seizures.<br />Hypersensitivity Reactions:<br />Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose,<br />have been reported in patients receiving quinolone therapy, including Noroxin&reg;. Some reactions<br />were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial<br />edema, dyspnea, urticaria and itching. Only a few patients had a history of hypersensitivity reactions.<br />If an allergic reaction to norfloxacin occurs, discontinue the drug. Serious acute hypersensitivity<br />reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous fluids,<br />antihistamines, corticosteroids, pressor amines, and airway management, including intubation,<br />should be administered as indicated.</u></p><p><u>Other serious and sometimes fatal events, some due to hypersensitivity, and some due to uncertain<br />etiology, have been reported rarely in patients receiving therapy with quinolones, including<br />Noroxin&reg;. These events may be severe and generally occur following the administration of multiple<br />doses. Clinical manifestations may include one or more of the following:<br />&bull;fever, rash or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson<br />syndrome);<br />&bull;vasculitis; arthralgia; myalgia; serum sickness;<br />&bull;allergic pneumonitis;<br />&bull;interstitial nephritis; acute renal insufficiency or failure;<br />&bull;hepatitis; jaundice; acute hepatic necrosis or failure;<br />&bull; anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic<br />thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic<br />abnormalities.<br />The drug should be discontinued immediately at the first appearance of a skin rash, jaundice, or any<br />other sign of hypersensitivity, and supportive measures should be instituted.<br />Clostridium Difficile Associated Diarrhea:<br />Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial<br />agents, including Noroxin&reg; and may range in severity from mild diarrhea to fatal colitis. Treatment<br />with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.<br />C. difficile produces toxins A and B which contribute to the development of CDAD.<br />Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as<br />theseinfections can be refractory to antimicrobial therapy and may require colectomy. CDAD must<br />beconsidered in all patients who present with diarrhea following antibiotic use. Careful medical<br />history is necessary since CDAD has been reported to occur over two months after the administration<br />of antibacterial agents.<br />If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need<br />to be discontinued. Appropriate fluid and electrolyte management, protein supplementation,<br />antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.<br />Peripheral Neuropathy:<br />Fluoroquinolones, including Noroxin&reg;, have been associated with an increased risk of peripheral<br />neuropathy. Rare Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or<br />large axons resulting in paresthesia, hypoesthesia, dysesthesias and weakness have been reported<br />in patients receiving fluoroquinolones, including Noroxin&reg;. Symptoms may occur soon after initiation<br />of norfloxacin and may be irreversible in some patients. Discontinue Noroxin&reg; immediately if the<br />patient experiences symptoms of peripheral neuropathy including pain, burning, tingling, numbness,<br />and/or weakness, or other alterations in sensations including light touch, pain, temperature, position<br />sense and vibratory sensation, and/or motor strength in order to minimize the development of an<br />irreversible condition.<br />Avoid fluoroquinolones, including Noroxin&reg;, in patients who have previously experienced peripheral<br />neuropathy.<br />Syphilis Treatment:<br />Norfloxacin has not been shown to be effective in the treatment of syphilis. Antimicrobial agents<br />used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of<br />incubating syphilis. All patients with gonorrhea should have a serologic test for syphilis at the time<br />of diagnosis. Patients treated with norfloxacin should have a follow-up serologic test for syphilis after<br />three months.</u></p><p><u>Precautions<br />General<br />Needle-shaped crystals were found in the urine of some volunteers who received either placebo, 800<br />mg norfloxacin, or 1600 mg norfloxacin (at or twice the recommended daily dose, respectively) while<br />participating in a double-blind, crossover study comparing single doses of norfloxacin with placebo.<br />While crystalluria is not expected to occur under usual conditions with a dosage regimen of 400 mg<br />twice daily, as a precaution, the daily recommended dosage should not be exceeded and the patient<br />should drink sufficient fluids to ensure a proper state of hydration and adequate urinary output.<br />Alteration in dosage regimen is necessary for patients with impaired renal function. (See Posology<br />and method of Administration section).<br />Moderate to severe photosensitivity/phototoxicity reactions<br />The latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema,<br />exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, &quot;V&quot; area of<br />the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of<br />quinolone antibiotics after sun or UV light exposure. Therefore, excessive exposure to these sources<br />of light should be avoided. Drug therapy should be discontinued if phototoxicity occurs.<br />Rarely, hemolytic reactions have been reported in patients with latent or actual defects in glucose-<br />6-phosphate dehydrogenase activity who take quinolone antibacterial agents, including norfloxacin.<br />Prescribing Noroxin&reg; in the absence of a proven or strongly suspected bacterial infection or a<br />prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the<br />development of drug-resistant bacteria.<br />Effects on ability to drive and use machines<br />Norfloxacin can cause dizziness and lightheadedness and, therefore, patients should know how they<br />react to norfloxacin before they operate an automobile or machinery or engage in activities requiring<br />mental alertness and coordination.<br />Cardiac Disorders<br />Caution should be taken when using fluoroquinolones, including norfloxacin, in patients with known<br />risk factors for prolongation of the QT interval such as, for example:<br />- Congenital long QT syndrome<br />- Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmic,<br />tricyclic antidepressants, Macrolides, antipsychotics).<br />- Uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesaemia).<br />- Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia).<br />- Elderly patients and women may be more sensitive to QTc-prolonging medications.<br />Therefore, caution should be taken when using fluoroquinolones, including norfloxacin, in<br />these populations.<br />Carcinogenesis, mutagenesis<br />No increase in neoplastic changes was observed with norfloxacin as compared to controls in a study<br />in rats, lasting up to 96 weeks at doses 8-9 times the usual human dose (on a mg/kg basis).<br />Norfloxacin was tested for mutagenic activity in a number of in vivo and in vitro tests. Norfloxacin<br />had no mutagenic effect in the dominant lethal test in mice and did not cause chromosomal</u></p><p><u>aberrations in hamsters or rats at doses 30-60 times the usual human dose (on a mg/kg basis).<br />Norfloxacin had no mutagenic activity in vitro in the Ames microbial mutagen test, Chinese hamster<br />fibroblasts and V-79 mammalian cell assay. Although norfloxacin was weakly positive in the Recassay<br />for DNA repair, all other mutagenic assays were negative including a more sensitive test (V-<br />79).<br />Aortic aneurysm and dissection, and heart valve regurgitation/incompetence<br />Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in<br />elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases<br />of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of<br />regurgitation/incompetence of any of the heart valves have been reported in patients receiving<br />fluoroquinolones (see section 4.8).<br />Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after<br />consideration of other therapeutic options in patients with positive family history of aneurysm<br />disease, or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm<br />and/or aortic dissection, or heart valve disease, or in presence of other risk factors or conditions<br />predisposing<br />- for both aortic aneurysm and dissection and heart valve regurgitation/incompetence<br />(e.g. connective tissue disorders such as Marfan syndrome or vascular Ehlers-Danlos<br />syndrome, Turner syndrome, Behcet&#39;s disease, hypertension, rheumatoid arthritis)<br />or additionally for aortic aneurysm and dissection ( e.g. vascular disorders such as<br />Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&rsquo;s<br />syndrome) or additionally<br />- for heart valve regurgitation/incompetence (e.g. infective endocarditis).<br />- The risk of aortic aneurysm and dissection, and their rupture may also be increased<br />in patients treated concurrently with systemic corticosteroids.<br />- In case of sudden abdominal, chest or back pain, patients should be advised to<br />immediately consult a physician in an emergency department.<br />Patients should be advised to seek immediate medical attention in case of acute<br />dyspnea, new onset of heart palpitations, or development of oedema of the<br />abdomen or lower extremities.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Quinolones, including norfloxacin, have been shown in vitro to inhibit CYP1A2. Concomitant use with<br />drugs metabolized by CYP1A2 (e.g., caffeine, clozapine, ropinirole, tacrine, theophylline,<br />tizanidine) may result in increased substrate drug concentrations when given in usual doses.<br />Patients taking any of these drugs concomitantly with norfloxacin should be carefully<br />monitored.<br />Elevated plasma levels of theophylline have been reported with concomitant quinolone use. There<br />have been reports of theophylline-related side effects in patients on concomitant therapy with<br />norfloxacin and theophylline. Therefore, monitoring of theophylline plasma levels should be<br />considered and dosage of theophylline adjusted as required.<br />Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with<br />norfloxacin. Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine<br />dosage adjustments made when these drugs are used concomitantly.<br />Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin<br />or its derivatives or similar agents. When these products are administered concomitantly,<br />prothrombin time or other suitable coagulation tests should be closely monitored.</p><p>The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea<br />agent) has, on rare occasions, resulted in severe hypoglycemia. Therefore, monitoring of blood<br />glucose is recommended when these agents are co-administered.<br />Diminished urinary excretion of norfloxacin has been reported during the concomitant<br />administration of probenecid and norfloxacin.<br />The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the<br />antibacterial effect of Noroxin&reg; in the urinary tract.<br />Multivitamins, or other products containing iron or zinc, antacids or sucralfate, should not be<br />administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because<br />they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.<br />Didanosine chewable/buffered tablets or the pediatric powder for oral solution should not be<br />administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because<br />these products may interfere with absorption resulting in lower serum and urine levels of<br />norfloxacin.<br />Some quinolones have also been shown to interfere with the metabolism of caffeine. This may lead<br />to reduced clearance of caffeine and a prolongation of the plasma half-life that may lead to<br />accumulation of caffeine in plasma when products containing caffeine are consumed while taking<br />norfloxacin. Ingestion of caffeine-containing medications (e.g. certain analgesics) should be avoided<br />where possible.<br />Oral nutritional solutions and dairy products (milk or milk products such as yoghurt) reduce the<br />absorption of norfloxacin. Norfloxacin should therefore be taken at least 1 hour before or 2 hours<br />after such products.<br />The concomitant administration of a non-steroidal anti-inflammatory drug (NSAID) with a quinolone,<br />including norfloxacin, may increase the risk of CNS stimulation and convulsive seizures. Therefore,<br />Noroxin&reg; should be used with caution in individuals receiving NSAIDS concomitantly. On the basis<br />of animal studies, concomitant administration of quinolones and fenbufen can cause seizures. Coadministration<br />of quinolones and fenbufen should therefore be avoided.<br />Norfloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs<br />known to prolong the QT interval (e.g. Class IA and III anti-arrhythmic, tricyclic antidepressants,<br />macrolides, antipsychotics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Fertility<br />Norfloxacin did not adversely affect the fertility of male and female mice at oral doses up to 30<br />times<br />the usual human dose (on a mg/kg basis).<br />Pregnancy<br />Teratogenic Effects.<br />Pregnancy Category C.<br />Norfloxacin has been shown to produce embryonic loss in monkeys when given in doses 10 times2<br />the maximum daily total human dose (on a mg/kg basis). At this dose, peak plasma levels obtained<br />in monkeys were approximately 2 times those obtained in humans. There has been no evidence<br />of a teratogenic effect in any of the animal species tested (rat, rabbit, mouse, monkey) at 6-50<br />times the maximum daily human dose (on a mg/kg basis). There are, however, no adequate and<br />well-controlled studies in pregnant women. Norfloxacin should be used during pregnancy only if the<br />potential benefit justifies the potential risk to the fetus.<br />Nursing Mothers<br />It is generally known that quinolones pass into mothers&rsquo; milk. It is not known whether norfloxacin,<br />specifically, is excreted in human milk.<br />When a 200-mg dose of Noroxin&reg; was administered to nursing mothers, norfloxacin was not<br />detected in human milk. However, because the dose studied was low, because other drugs in this<br />class are secreted in human milk, and because of the potential for serious adverse reactions from<br />norfloxacin in nursing infants, a decision should be made to discontinue nursing or to discontinue<br />the drug, taking into account the importance of the drug to the mother.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pediatric Use<br />The safety and effectiveness of oral norfloxacin in pediatric patients and adolescents below the age<br />of 18 years have not been established. Norfloxacin causes arthropathy in juvenile animals of several<br />animal species. (See SPECIAL WARNINGS AND PRECAUTIONS section)<br />Geriatric Use<br />Geriatric patients are at increased risk for developing severe tendon disorders including tendon<br />rupture when being treated with a fluoroquinolone such as Noroxin&reg;. This risk is further increased<br />in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve<br />the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of<br />therapy; cases occurring up to several months after fluoroquinolone treatment have been reported.<br />Caution should be used when prescribing Noroxin&reg; to elderly patients, especially those on<br />corticosteroids. Patients should be informed of this potential side effect and advised to discontinue<br />Noroxin&reg; and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur<br />(see Boxed Warning; WARNINGS; and ADVERSE REACTIONS, Post-Marketing). Of the 340 subjects in<br />one large clinical study of Noroxin&reg; for treatment of urinary tract infections, 103 patients were 65<br />and older, 77 of whom were 70 and older; no overall differences in safety and effectiveness were<br />evident between these subjects and younger subjects. In clinical practice, no difference in the type<br />of reported adverse experiences have been observed between the elderly and younger patients<br />except for a possible increased risk of tendon rupture in elderly patients receiving concomitant<br />corticosteroids (see SPECIAL WARNINGS and PRECAUTIONS section). In addition, increased risk for<br />other adverse experiences in some older individuals cannot be ruled out (see Undesirable Effects<br />section).<br />This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this<br />drug may be greater in patients with impaired renal function. Because elderly patients are more likely<br />to have decreased renal function, care should be taken in dose selection, and it may be useful to<br />monitor renal function (see POSOLOGY and METHOD OF ADMINISTRATION). A pharmacokinetic<br />study of Noroxin&reg; in elderly volunteers (65 to 75 years of age with normal renal function for their<br />age) was carried out (see CLINICAL PHARMACOLOGICAL PROPERTIES). In general, elderly patients<br />may be more susceptible to drug-associated effects of the QTc interval. Therefore, precaution should<br />be taken when using Noroxin&reg; concomitantly with drugs that can result in prolongation of the QTc<br />interval (e.g., class IA or class III antiarrhythmic) or in patients with risk factors for torsade de pointes<br />(e.g., known QTc prolongation, uncorrected hypokalemia).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Single-Dose Studies<br />In clinical trials involving 82 healthy subjects and 228 patients with gonorrhea, treated with a single<br />dose of norfloxacin, 6.5% reported drug-related adverse experiences. However, the following<br />incidence figures were calculated without reference to drug relationship.<br />The most common adverse experiences (&gt;1.0%) were: dizziness (2.6%), nausea (2.6%), headache<br />(2.0%), and abdominal cramping (1.6%).<br />Additional reactions (0.3%-1.0%) were: anorexia, diarrhea, hyperhidrosis, asthenia, anal/rectal pain,<br />constipation, dyspepsia, flatulence, tingling of the fingers, and vomiting.<br />Laboratory adverse changes considered drug-related were reported in 4.5% of patients/subjects.<br />These laboratory changes were: increased AST (SGOT) (1.6%), decreased W BC (1.3%), decreased<br />platelet count (1.0%), increased urine protein (1.0%), decreased hematocrit and hemoglobin<br />(0.6%), and increased eosinophils (0.6%).<br />Multiple-Dose Studies<br />In clinical trials involving 52 healthy subjects and 1980 patients with urinary tract infections or<br />prostatitis treated with multiple doses of norfloxacin, 3.6% reported drug-related adverse<br />experiences. However, the incidence figures below were calculated without reference to drug<br />relationship.<br />The most common adverse experiences (&gt;1.0%) were: nausea (4.2%), headache (2.8%), dizziness<br />(1.7%), and asthenia (1.3%).<br />Additional reactions (0.3%-1.0%) were: abdominal pain, back pain, constipation, diarrhea, dry mouth,<br />dyspepsia/heartburn, fever, flatulence, hyperhidrosis, loose stools, pruritus, rash, somnolence, and<br />vomiting.<br />Less frequent reactions (0.1%-0.2%) included: abdominal swelling, allergies, anorexia, anxiety, bitter<br />taste, blurred vision, bursitis, chest pain, chills, depression, dysmenorrhea, edema, erythema, foot or<br />hand swelling, insomnia, mouth ulcer, myocardial infarction, palpitation, pruritus, renal colic, sleep<br />disturbances, and urticaria.<br />Abnormal laboratory values observed in these patients/subjects were: eosinophilia (1.5%), elevation<br />of ALT (SGPT) (1.4%), decreased W BC and/or neutrophil count (1.4%), elevation of AST (SGOT) (1.4%),<br />and increased alkaline phosphatase (1.1%).<br />Those occurring less frequently included increased BUN, increased LDH, increased serum creatinine,<br />decreased hematocrit, and glycosuria.<br />Post-Marketing<br />The most frequently reported adverse reaction in post-marketing experience is rash.<br />CNS effects characterized as generalized seizures, myoclonus and tremors have been reported with<br />Noroxin&reg;. Visual disturbances have been reported with drugs in this class.<br />The following additional adverse reactions have been reported since the drug was marketed:<br />Hypersensitivity Reactions2<br />Hypersensitivity reactions have been reported including anaphylactic reactions, angioedema,<br />dyspnea, vasculitis, urticaria, arthritis, arthralgia and myalgia.</em></p><p><em>Skin<br />Toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiform, exfoliative<br />dermatitis, photosensitivity/phototoxicity reactions, leukocytoclastic vasculitis, drug rash with<br />eosinophilia and systemic symptoms (DRESS syndrome).<br />Gastrointestinal<br />Pseudomembranous colitis, hepatitis, jaundice including cholestatic jaundice and elevated liver<br />function tests, pancreatitis (rare), stomatitis. The onset of pseudomembranous colitis symptoms may<br />occur during or after antibacterial treatment.<br />Hepatic<br />Hepatic failure, including fatal cases.<br />Cardiovascular1<br />On rare occasions, prolonged QTc interval and ventricular arrhythmia including torsade de pointes.<br />Renal<br />Interstitial nephritis, renal failure.<br />Nervous System/Psychiatric2<br />Peripheral neuropathy that may be irreversible, Guillain-Barre syndrome, ataxia, paresthesia,<br />hypoesthesia, psychic disturbances including psychotic reactions and confusion.<br />Musculoskeletal2<br />Tendinitis, tendon rupture; exacerbation of myasthenia gravis (see WARNINGS, Exacerbation of<br />myasthenia gravis); elevated creatine kinase (CK), muscle spasms.<br />Hematologic<br />Neutropenia; leukopenia; agranulocytosis; hemolytic anemia, sometimes associated with glucose-6-<br />phosphate dehydrogenase deficiency; thrombocytopenia.<br />Special Senses2<br />Hearing loss, tinnitus, diplopia, dysgeusia. uveitis<br />Fluoroquinolones may cause significant decreases in blood sugar and certain mental health side<br />effects.<br />Blood sugar disturbance: hypoglycemia can lead to coma<br />The mental health side effects are:<br />Disturbances in attention, Disorientation, Agitation, Nervousness, Memory impairment, Delirium.<br />Other adverse events reported with quinolones include: agranulocytosis, albuminuria, candiduria,<br />crystalluria, cylindruria, dysphagia, elevation of blood glucose, elevation of serum cholesterol,<br />elevation of serum potassium, elevation of serum triglycerides, hematuria, hepatic necrosis,<br />symptomatic hypoglycemia, nystagmus, postural hypotension, prolongation of prothrombin time,<br />1 Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence<br />of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).<br />Other adverse events reported with quinolones include: agranulocytosis, albuminuria, candiduria, crystalluria, cylindruria, dysphagia,<br />elevation of blood glucose, elevation of serum cholesterol, elevation of serum potassium, elevation of serum triglycerides, hematuria,<br />hepatic necrosis, symptomatic hypoglycemia, nystagmus, postural hypotension, prolongation of prothrombin time, and vaginal<br />candidiasis.<br />2 Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several,<br />sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in<br />extremities, gait disturbance, neuropathies associated with paresthesia, depression, fatigue, memory impairment, sleep disorders, and<br />impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in<br />some cases irrespective of pre-existing risk factors (see Section 4.4).</em></p><p><em>and vaginal candidiasis.<br />To report any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Center (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext: 2317-2356--2340<br />Reporting hotline: 19999<br />Email: npc.drug@sfda.gov.sa<br />Website: www. sfda.gov.sa/npc</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No significant lethality was observed in male and female mice and rats at single oral doses up to<br />4 g/kg.<br />In the event of acute over dosage, the stomach should be emptied by inducing vomiting or by gastric<br />lavage, and the patient carefully observed and given symptomatic and supportive treatment.<br />Adequate hydration must be maintained.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action<br />Norfloxacin inhibits bacterial deoxyribonucleic acid synthesis and is bactericidal. At the molecular<br />level, three specific events are attributed to norfloxacin in E. coli cells:<br />1) inhibition of the ATP-dependent DNA supercoiling reaction catalyzed by DNA gyrase,<br />2) inhibition of the relaxation of supercoiled DNA,<br />3) promotion of double-stranded DNA breakage.<br />The fluorine atom at the 6 position provides increased potency against gram-negative organisms, and<br />the piperazine moiety at the 7 position is responsible for antipseudomonal activity.<br />Drug Resistance<br />Resistance to norfloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10-9 to<br />10-12 cells). Resistant organisms have emerged during therapy with norfloxacin in less than 1% of<br />patients treated. Organisms in which development of resistance is greatest are the following:<br />Pseudomonas aeruginosa<br />Klebsiella pneumoniae<br />Acinetobacter spp.<br />Enterococcus spp.<br />For this reason, when there is a lack of satisfactory clinical response, repeat culture and susceptibility<br />testing should be done. Nalidixic acid-resistant organisms are generally susceptible to norfloxacin in<br />vitro; however, these organisms may have higher minimum inhibitory concentrations (MICs) to<br />norfloxacin than nalidixic acid-susceptible strains. There is generally no cross-resistance between<br />norfloxacin and other classes of antibacterial agents. Therefore, norfloxacin may demonstrate<br />activity against indicated organisms resistant to some other antimicrobial agents including the<br />aminoglycosides, penicillins, cephalosporins, tetracyclines, macrolides, and sulfonamides, including</p><p>combinations of sulfamethoxazole and trimethoprim. Antagonism has been demonstrated in vitro<br />between norfloxacin and nitrofurantoin.<br />Activity in vitro and in vivo<br />Norfloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic<br />bacteria.<br />Norfloxacin has been shown to be active against most strains of the following microorganisms both<br />in vitro and in clinical infections.<br />Gram-positive aerobes :<br />Enterococcus faecalis<br />Staphylococcus aureus<br />Staphylococcus epidermidis<br />Staphylococcus saprophyticus<br />Streptococcus agalactiae<br />Gram-negative aerobes :<br />Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli<br />Klebsiella pneumonia<br />Neisseria gonorrhoeae<br />Proteus mirabilis<br />Proteus vulgaris<br />Pseudomonas aeruginosa<br />Serratia marcescens<br />The following in vitro data are available, but their clinical significance is unknown.<br />Norfloxacin exhibits in vitro MICs of &le;4 &mu;g/mL against most (&ge;90%) strains of the following<br />microorganisms; however, the safety and effectiveness of norfloxacin in treating clinical infections<br />due to these microorganisms have not been established in adequate and well-controlled clinical<br />trials.<br />Gram-negative aerobes:<br />Citrobacter diversus<br />Edwardsiella tarda<br />Enterobacter agglomerans<br />Haemophilus ducreyi<br />Klebsiella oxytoca<br />Morganella morganii<br />Providencia alcalifaciens<br />Providencia rettgeri<br />Providencia stuartii<br />Pseudomonas fluorescens<br />Pseudomonas stutzeri<br />Other:<br />Ureaplasma urealyticum<br />Noroxin&reg; is not generally active against obligate anaerobes. Norfloxacin has not been shown to be&nbsp;active against Treponema pallidum.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In fasting healthy volunteers, at least 30-40% of an oral dose of Noroxin&reg; is absorbed. Absorption<br />is rapid following single doses of 200 mg, 400 mg and 800 mg. At the respective doses, mean peak<br />serum and plasma concentrations of 0.8, 1.5 and 2.4 &mu;g/mL are attained approximately one hour<br />after dosing. The presence of food and/or dairy products may decrease absorption. The effective<br />half-life of norfloxacin in serum and plasma is 3-4 hours. Steady-state concentrations of norfloxacin<br />will be attained within two days of dosing.<br />In healthy elderly volunteers (65-75 years of age with normal renal function for their age),<br />norfloxacin is eliminated more slowly because of their slightly decreased renal function. Following<br />a single 400-mg dose of norfloxacin, the mean (&plusmn; SD) AUC and Cmax of 9.8 (2.83) &mu;g.h/mL and<br />2.02 (0.77) &mu;g/mL, respectively, were observed in healthy elderly volunteers. The extent of systemic<br />exposure was slightly higher than that seen in younger adults (AUC 6.4 &mu;g.h/mL and Cmax 1.5<br />&mu;g/mL). Drug absorption appears unaffected. However, the effective half-life of norfloxacin in these<br />elderly subjects is 4 hours.<br />There is no information on accumulation of norfloxacin with repeated administration in elderly<br />patients. However, no dosage adjustment is required based on age alone. In elderly patients<br />with reduced renal function, the dosage should be adjusted as for other patients with renal<br />impairment (see Posology and Method of Administration, Renal Impairment).<br />The disposition of norfloxacin in patients with creatinine clearance rates greater than 30<br />mL/min/1.73 m2 is similar to that in healthy volunteers. In patients with creatinine clearance rates<br />equal to or less than 30 mL/min/1.73 m2, the renal elimination of norfloxacin decreases so that the<br />effective serum half-life is 6.5 hours. In these patients, alteration of dosage is necessary (see DOSAGE<br />AND ADMINISTRATION). Drug absorption appears unaffected by decreasing renal function.<br />Norfloxacin is eliminated through metabolism, biliary excretion, and renal excretion. After a single<br />400-mg dose of Noroxin&reg;, mean antimicrobial activities equivalent to 278, 773, and 82 &mu;g of<br />norfloxacin/g of feces were obtained at 12, 24, and 48 hours, respectively. Renal excretion occurs<br />by both glomerular filtration and tubular secretion as evidenced by the high rate of renal clearance<br />(approximately 275 mL/min). Within 24 hours of drug administration, 26 to 32% of the administered<br />dose is recovered in the urine as norfloxacin with an additional 5-8% being recovered in the urine<br />as six active metabolites of lesser antimicrobial potency. Only a small percentage (less than 1%)<br />of the dose is recovered thereafter. Fecal recovery accounts for another 30% of the administered<br />dose. In elderly subjects (average creatinine clearance 91 mL/min/1.73 m2) approximately 22% of<br />the administered dose was recovered in urine and renal clearance averaged 154 mL/min.<br />Two to three hours after a single 400-mg dose, urinary concentrations of 200 &mu;g/mL or more are<br />attained in the urine. In healthy volunteers, mean urinary concentrations of norfloxacin remain<br />above 30 &mu;g/mL for at least 12 hours following a 400-mg dose. The urinary pH may affect the<br />solubility of norfloxacin. Norfloxacin is least soluble at urinary pH of 7.5 with greater solubility<br />occurring at pHs above and below this value. The serum protein binding of norfloxacin is<br />between 10 and 15%.<br />The following are mean concentrations of norfloxacin in various fluids and tissues measured 1 to<br />4 hours post-dose after two 400-mg doses, unless otherwise indicated:<br />Renal Parenchyma 7.3&mu;g/g<br />Prostate 2.5&mu;g/g<br />Seminal Fluid 2.7&mu;g/Ml<br />Testicle 1.6&mu;g/g<br />Uterus/Cervix 3.0&mu;g/g<br />Vagina 4.3&mu;g/g<br />Fallopian Tube 1.9&mu;g/g<br />Bile 6.9 &mu;g/mL (after two 200-mg doses)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose,<br />Croscarmellose sodium,<br />magnesium stearate,<br />hydroxypropylmethylcellulose,<br />hydroxy-propylcellulose,<br />titanium dioxide,<br />carnauba wax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of reach and sight of children.<br />Do not store above 30&deg;C.<br />Store in the original package.<br />Do not use Noroxin&reg; tablets after the expiry date stated on the carton and the blisters.<br />The expiry date refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Noroxin&reg; tablets are white, film-coated, oval-shaped biconvex tablets, one side scored, the other<br />engraved &lsquo;ALG N400&rsquo;.<br />Noroxin&reg; is available in packs of 14 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Algorithm SAL - Lebanon
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>